Genmab — Juni 2019
-
Han noterer dog også:Daratumumab-salget bør dog kunne femdobles frem mod 2025, og vi ser positivt på aktiens langsigtede potentiale, skriver Simon Hagbart Madsen.
-
ADC Therapeutics / ADCT-301 (camidanlumab - https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/ https://www.globenewswire.com/news-release/2019/06/12/1867420/0/en/ADC-Therapeutics-Announces-Presentations-at-the-15th-International-Conference-on-Malignant-Lymphoma.html?culture=en-us
-
Mon ikke godkendelsen kommer i H1. Der er jo stadig 20 dage
så hvorfor forsøge JB mon at piske en halv negativ meddelelse. De 2.5 mia er jo hjemme selv uden nogen salgsstigning med udgangspunkt i Q1 som var 630 mil x 4 = 2.516. Så jeg vil sige selv med kun 4 mdr 1 line salg er 3 bn sandlynligvis mulig -
Du kan have ret..Jyske kan have ret..jeg kan have ret...alle kan have ret.
-
Nogle håber..andre tror...men ingen ved!
-
Måske er FDA i gang med en større cost/benefit analyse.
-
altså vi når i mål med 15% stigning per kvartal
-
- maj udtaler FDA: The Real-Time Oncology Review Program is a pilot program and we are continuing to evaluate drug applications on a case by case basis" https://www.raps.org/news-and-articles/news-articles/2019/5/fda-approves-first-nda-under-real-time-oncology-re
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind